IP Library Assignment 073164/0032
Patent Assignment
Reel/Frame 073164/0032

Patent Security Agreement

Recorded: 2025-10-20 Pages: 20
Assignors
VALNEVA AUSTRIA GMBH
Executed: 2025-10-17
VALNEVA SE
Executed: 2025-10-17
VALNEVA SWEDEN AB
Executed: 2025-10-17
Assignee
BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
C/O BEAUFORT HOUSE, 51 NEW NORTH ROAD, EXETER, EX4 4EP, UNITED KINGDOM
Covered Properties (67)
Methods and Compositions Involving Immunostimulatory Oligodeoxynucleotides
Patent: 8,568,742 →
Application: 10/297,555 →
Publication: US 2003/0171321
Vaccine Composition Comprising an Antigen and a Peptide Having Adjuvant Properties
Patent: 8,361,476 →
Application: 10/399,442 →
Publication: US 2005/0063978
Vaccines
Patent: 7,704,514 →
Application: 10/550,754 →
Publication: US 2006/0263386
Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines
Patent: 8,148,132 →
Application: 11/918,206 →
Publication: US 2009/0081251
A Method of Obtaining Chicken Embryonic Stem Cells
Patent: 8,962,311 →
Application: 12/376,660 →
Publication: US 2010/0235937
Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines
Patent: 9,040,296 →
Application: 13/423,195 →
Publication: US 2012/0238001
Aluminum Compounds for Use in Therapeutics and Vaccines
Patent: 9,895,437 →
Application: 13/449,596 →
Publication: US 2013/0280295
MUTANT FRAGMENTS OF OspA AND METHODS AND USES RELATING THERETO
Patent: 8,986,704 →
Application: 13/802,991 →
Publication: US 2014/0010835
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Patent: 9,598,472 →
Application: 14/342,565 →
Publication: US 2015/0056238
Production of Viral Vaccines in Suspension on Avian Embryonic Derived Stem Cell Lines
Patent: 9,701,945 →
Application: 14/718,393 →
Publication: US 2015/0275186
Aluminum Compounds for Use in Therapeutics and Vaccines
Patent: 9,884,115 →
Application: 14/873,344 →
Publication: US 2016/0114033
Method of Making a Virus Using Duck Embryonic Derived Stem Cell Lines
Patent: 9,822,345 →
Application: 15/013,079 →
Publication: US 2016/0257940
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Patent: 9,975,927 →
Application: 15/110,151 →
Publication: US 2016/0333056
Aluminum Compounds for Use in Therapeutics and Vaccines
Patent: 9,913,898 →
Application: 15/223,027 →
Publication: US 2016/0324959
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Patent: 9,926,343 →
Application: 15/267,372 →
Publication: US 2017/0107263
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 15/272,581 →
Publication: US 2017/0101446
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 15/421,808 →
Publication: US 2017/0239340
Methods for Preparing Aluminum Precipitate Compounds for Use in Therapeutics and Vaccines
Application: 15/469,689 →
Publication: US 2017/0296656
Aseptic Purification Process for Viruses
Application: 15/561,094 →
Publication: US 2018/0119110
Zika Virus Purification
Application: 15/781,825 →
Publication: US 2018/0362936
Virus Purification
Application: 15/781,959 →
Publication: US 2018/0362937
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 15/906,618 →
Publication: US 2018/0327460
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 15/944,835 →
Publication: US 2018/0362593
Zika Virus Purification
Application: 16/060,054 →
Publication: US 2019/0008945
Virus Purification
Application: 16/062,245 →
Publication: US 2018/0369359
Zika Virus Vaccine
Application: 16/063,007 →
Publication: US 2018/0371027
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 16/295,031 →
Publication: US 2019/0290747
Multivalent Ospa Polypeptides and Methods and Uses Relating Thereto
Application: 16/497,178 →
Publication: US 2023/0151063
Method of Producing Pharmaceutical Compositions Comprising Immunogenic Chikungunya Virus Chikv-DELTA5NSP3
Application: 16/641,012 →
Publication: US 2021/0322534
Virus Purification
Application: 16/702,764 →
Publication: US 2020/0197506
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 16/702,885 →
Publication: US 2020/0239525
Aluminum Compounds for Use in Therapeutics and Vaccines
Application: 16/734,866 →
Publication: US 2020/0360511
Zika Virus Vaccine
Application: 16/813,862 →
Publication: US 2020/0384099
Aseptic Purification Process for Viruses
Application: 16/815,215 →
Publication: US 2020/0347364
Virus Purification
Application: 16/840,760 →
Publication: US 2020/0368342
Zika Virus Purification
Application: 16/927,086 →
Publication: US 2021/0093707
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 16/990,023 →
Publication: US 2021/0054032
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 17/061,891 →
Publication: US 2021/0121554
Method for Rescuing and Producing a Virus in Avian Cells
Application: 17/260,054 →
Publication: US 2021/0275662
Methods for Preparing Aluminum Precipitate Compounds for Use in Therapeutics and Vaccines
Application: 17/393,888 →
Publication: US 2022/0125917
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 17/406,765 →
Publication: US 2021/0393761
Method of Producing Pharmaceutical Compositions Comprising Immunogenic Chikungunya Virus Chikv-DELTA5NP3
Application: 17/407,499 →
Publication: US 2022/0016230
CpG-ADJUVANTED SARS-CoV-2 VIRUS VACCINE
Application: 17/471,904 →
Publication: US 2023/0038284
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 17/517,477 →
Publication: US 2022/0185851
Zika Virus Vaccine
Application: 17/548,721 →
Publication: US 2022/0273786
Chikungunya Vaccine Formulations
Application: 17/632,943 →
Publication: US 2022/0288185
Single Shot Chikungunya Virus Vaccine
Application: 17/632,946 →
Publication: US 2022/0313810
Inactivation Process for Viruses
Application: 17/688,960 →
Publication: US 2022/0298493
Coronavirus Vaccines Comprising a TLR9 Agonist
Application: 17/802,361 →
Publication: US 2023/0092650
Virus Purification
Application: 17/811,059 →
Publication: US 2023/0056142
Improvements in Vaccine Formulations for Medical Use
Application: 17/917,010 →
Publication: US 2023/0398210
Improved Methods of Producing a Lipidated Protein
Application: 17/917,016 →
Publication: US 2024/0026412
Compositions Comprising Three Ospa Fusion Proteins for Medical Use
Application: 17/917,624 →
Publication: US 2023/0173051
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 17/930,742 →
Publication: US 2023/0173052
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 17/932,226 →
Publication: US 2023/0295245
Method of Producing Pharmaceutical Compositions Comprising Immunogenic Chikungunya Virus Chikv-DELTA5NSP3
Application: 17/935,490 →
Publication: US 2023/0293661
Cholera Vaccine Formulation
Application: 18/027,657 →
Publication: US 2023/0372464
Mutant Fragments of Ospa and Methods and Uses Relating Thereto
Application: 18/150,971 →
Publication: US 2023/0322869
Zika Virus Vaccine
Application: 18/178,638 →
Publication: US 2023/0226165
Zika Virus Vaccine
Application: 18/334,497 →
Publication: US 2024/0108712
Method of Producing Pharmaceutical Compositions Comprising Immunogenic Chikungunya Virus Chikv-DELTA5NSP3
Application: 18/655,777 →
Publication: US 2025/0073326
Multivalent Ospa Polypeptides and Methods and Uses Relating Thereto
Application: 18/665,018 →
Publication: US 2025/0101069
Zika Virus Vaccine
Application: 18/799,291 →
Publication: US 2025/0018023
Clostridium Difficile Vaccine
Application: 18/867,201 →
Publication: US 2025/0213667
Process for Virus Production in a Bioreactor
Application: 19/147,841 →
Immunogenic Chikungunya Compositions for Administration to Immunocompromised Patients
Application: 19/162,120 →
Isolated Polypeptide of the Toxin a and Toxin B Proteins of C. Difficile and Uses Thereof
Application: 19/202,001 →
Publication: US 2025/0360191
Related Assignments (25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 17, 2003
From: FRITZ, JORG; MATTNER, FRANK; ZAUNER, WOLFGANG; NAGY, ESZTER
To: INTERCELL BIOMEDIZINISCHE FORSCHUNGS-UND ENTWICKLUNGS AG
Reel/Frame 014400/0764 →
Change of Name Feb 9, 2007
From: INTERCELL BIOMEDIZINISCHE FORSCHUNGS-UND ENTWICKLUNGS AG
To: INTERCELL AG
Reel/Frame 018876/0637 →
Assignment of Assignor's Interest Mar 29, 2007
From: BUSCHLE, MICHAEL; HABEL, ANDRE; FRITZ, JORG; PRINZ, KARIN
To: INTERCELL AG
Reel/Frame 019085/0711 →
Assignment of Assignor's Interest Jan 14, 2009
From: MEHTALI, MAJID; CHAMPION-ARNAUD, PATRICK; LEON, ARNAUD
To: VIVALIS
Reel/Frame 022106/0677 →
Assignment of Assignor's Interest Apr 21, 2010
From: VALARCHE, ISABELLE; BATARD, LUC; MEHTALI, MAJID
To: VIVALIS
Reel/Frame 024264/0067 →
Assignment of Assignor's Interest Jun 12, 2012
From: SCHLEGL, ROBERT; MOHLEN, MICHAEL; WRUSS, JURGEN; WEBER, MICHAEL
To: INTERCELL AG
Reel/Frame 028358/0972 →
Assignment of Assignor's Interest Jun 4, 2013
From: COMSTEDT, PAR; HANNER, MARKUS; LUNDBERG, URBAN; MEINKE, ANDREAS
To: INTERCELL AG
Reel/Frame 030541/0775 →
Asset Transfer Agreement Jun 13, 2013
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 030610/0627 →
Asset Transfer Agreement Sep 25, 2013
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 031283/0233 →
Change of Name Sep 25, 2013
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 031283/0473 →
Change of Name Jan 24, 2014
From: VIVALIS
To: VALNEVA
Reel/Frame 032036/0864 →
Change of Name Mar 21, 2014
From: VIVALIS
To: VALNEVA
Reel/Frame 032497/0739 →
Asset Transfer Agreement Apr 10, 2014
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 032651/0786 →
Change of Name Apr 10, 2014
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 032642/0164 →
Assignment of Assignor's Interest Sep 9, 2014
From: GUEHENNEUX, FABIENNE
To: VALNEVA
Reel/Frame 033697/0396 →
Change of Name Sep 26, 2014
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 033824/0026 →
Assignment of Assignor's Interest Oct 30, 2014
From: WESTRITSCHNIG, KERSTIN
To: VALNEVA AUSTRIA GMBH
Reel/Frame 034067/0290 →
Assignment of Assignor's Interest Oct 30, 2014
From: ELLINGSWORTH, LARRY R.; FLYER, DAVID; TIAN, JING-HUI; FUHRMANN, STEVEN R.
To: INTERCELL USA, INC.
Reel/Frame 034067/0261 →
Asset Transfer Agreement Dec 17, 2014
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 034659/0640 →
Change of Name Dec 17, 2014
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 034524/0311 →
Change of Name May 18, 2016
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 038636/0555 →
Assignment of Assignor's Interest May 18, 2016
From: SCHLEGL, ROBERT; MOHLEN, MICHAEL; WRUSS, JURGEN; WEBER, MICHAEL
To: INTERCELL AG
Reel/Frame 038746/0225 →
Asset Transfer Agreement May 18, 2016
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 038746/0240 →
Change of Name Aug 22, 2016
From: VIVALIS SA
To: VALNEVA
Reel/Frame 039498/0958 →
Assignment of Assignor's Interest Aug 22, 2016
From: SCHLEGL, ROBERT; MOHLEN, MICHAEL; WRUSS, JURGEN; WEBER, MICHAEL
To: INTERCELL AG
Reel/Frame 039771/0993 →